Omeros Corp
OMER11.230USD
+0.490+4.56%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
786.93MCap. mercado
PérdidaP/E TTM
Más Datos de Omeros Corp Compañía
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Its lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
Información de Omeros Corp
Símbolo de cotizaciónOMER
Nombre de la empresaOmeros Corp
Fecha de salida a bolsaOct 08, 2009
Director ejecutivoDemopulos (Gregory A)
Número de empleados202
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 08
Dirección201 Elliott Avenue West
CiudadSEATTLE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal98119
Teléfono12066765000
Sitio Webhttps://www.omeros.com/
Símbolo de cotizaciónOMER
Fecha de salida a bolsaOct 08, 2009
Director ejecutivoDemopulos (Gregory A)
Ejecutivos de Omeros Corp
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Peter A. Demopulos, M.D.
Dr. Peter A. Demopulos, M.D.
Director
Director
372.90K
--
Dr. Leroy E. Hood, M.D., Ph.D.
Dr. Leroy E. Hood, M.D., Ph.D.
Independent Director
Independent Director
74.39K
--
Mr. Thomas J. Cable
Mr. Thomas J. Cable
Lead Independent Director
Lead Independent Director
35.07K
--
Mr. Arnold C. Hanish, CPA
Mr. Arnold C. Hanish, CPA
Independent Director
Independent Director
12.40K
--
DR. Gregory A. Demopulos, M.D.
DR. Gregory A. Demopulos, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Rajiv Shah, M.D.
Dr. Rajiv Shah, M.D.
Independent Director
Independent Director
--
--
Dr. Thomas F. Bumol, Ph.D.
Dr. Thomas F. Bumol, Ph.D.
Independent Director
Independent Director
--
--
Dr. George A. Gaitanaris, M.D., Ph.D.
Dr. George A. Gaitanaris, M.D., Ph.D.
Vice President - Science, Chief Scientific Officer
Vice President - Science, Chief Scientific Officer
--
--
Dr. Catherine A. Melfi, Ph.D.
Dr. Catherine A. Melfi, Ph.D.
Vice President - Regulatory Affairs and Quality Systems, Chief Regulatory Officer
Vice President - Regulatory Affairs and Quality Systems, Chief Regulatory Officer
--
--
Dr. J. Steven Whitaker, M.D., J.D.
Dr. J. Steven Whitaker, M.D., J.D.
Vice President - Clinical Development
Vice President - Clinical Development
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Peter A. Demopulos, M.D.
Dr. Peter A. Demopulos, M.D.
Director
Director
372.90K
--
Dr. Leroy E. Hood, M.D., Ph.D.
Dr. Leroy E. Hood, M.D., Ph.D.
Independent Director
Independent Director
74.39K
--
Mr. Thomas J. Cable
Mr. Thomas J. Cable
Lead Independent Director
Lead Independent Director
35.07K
--
Mr. Arnold C. Hanish, CPA
Mr. Arnold C. Hanish, CPA
Independent Director
Independent Director
12.40K
--
DR. Gregory A. Demopulos, M.D.
DR. Gregory A. Demopulos, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Rajiv Shah, M.D.
Dr. Rajiv Shah, M.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: vie., 5 de dic
Actualizado: vie., 5 de dic
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Ingalls & Snyder LLC (Asset Management)
5.79%
BlackRock Institutional Trust Company, N.A.
5.78%
The Vanguard Group, Inc.
5.66%
UBS Financial Services, Inc.
3.13%
Stifel, Nicolaus & Company, Incorporated
2.56%
Otro
77.08%
Accionistas
Accionistas
Proporción
Ingalls & Snyder LLC (Asset Management)
5.79%
BlackRock Institutional Trust Company, N.A.
5.78%
The Vanguard Group, Inc.
5.66%
UBS Financial Services, Inc.
3.13%
Stifel, Nicolaus & Company, Incorporated
2.56%
Otro
77.08%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
18.92%
Investment Advisor/Hedge Fund
16.92%
Hedge Fund
7.52%
Research Firm
5.37%
Individual Investor
2.74%
Bank and Trust
0.86%
Insurance Company
0.12%
Pension Fund
0.07%
Otro
47.47%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
254
35.16M
49.59%
+4.61M
2025Q3
243
29.83M
43.83%
+1.23M
2025Q2
255
30.16M
44.94%
-422.08K
2025Q1
263
30.38M
51.89%
-522.27K
2024Q4
256
29.32M
50.59%
-441.66K
2024Q3
242
27.89M
48.13%
-1.92M
2024Q2
248
27.65M
47.72%
-3.10M
2024Q1
269
28.11M
48.16%
-3.03M
2023Q4
275
27.52M
43.79%
-6.21M
2023Q3
299
30.25M
48.14%
-4.77M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Ingalls & Snyder LLC (Asset Management)
4.11M
5.79%
+123.69K
+3.11%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
4.10M
5.78%
+401.97K
+10.88%
Sep 30, 2025
The Vanguard Group, Inc.
3.35M
4.72%
+63.38K
+1.93%
Sep 30, 2025
UBS Financial Services, Inc.
701.35K
0.99%
-157.44K
-18.33%
Sep 30, 2025
Stifel, Nicolaus & Company, Incorporated
1.81M
2.56%
+289.38K
+19.00%
Sep 30, 2025
Morgan Stanley & Co. LLC
1.59M
2.25%
+507.73K
+46.75%
Sep 30, 2025
Geode Capital Management, L.L.C.
1.54M
2.17%
+165.50K
+12.08%
Sep 30, 2025
Two Sigma Investments, LP
1.51M
2.13%
+418.50K
+38.29%
Sep 30, 2025
Polar Asset Management Partners Inc.
1.50M
2.11%
+1.50M
--
Sep 30, 2025
Demopulos (Gregory A. M.D.)
1.43M
2.01%
-600.00K
-29.60%
Oct 13, 2025
Ver más
ETFs relacionados
Actualizado: mar., 2 de dic
Actualizado: mar., 2 de dic
Nombre
Proporción
Invesco NASDAQ Future Gen 200 ETF
0.94%
iShares Micro-Cap ETF
0.09%
Invesco Nasdaq Biotechnology ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.05%
ProShares UltraPro Russell2000
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
Proshares Ultra Russell 2000
0.02%
ProShares Hedge Replication ETF
0.02%
iShares Russell 2000 Growth ETF
0.02%
Global X Russell 2000 ETF
0.02%
Ver más
Invesco NASDAQ Future Gen 200 ETF
Proporción0.94%
iShares Micro-Cap ETF
Proporción0.09%
Invesco Nasdaq Biotechnology ETF
Proporción0.05%
ProShares Ultra Nasdaq Biotechnology
Proporción0.05%
ProShares UltraPro Russell2000
Proporción0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0.02%
Proshares Ultra Russell 2000
Proporción0.02%
ProShares Hedge Replication ETF
Proporción0.02%
iShares Russell 2000 Growth ETF
Proporción0.02%
Global X Russell 2000 ETF
Proporción0.02%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
